Your browser doesn't support javascript.
loading
Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors.
Barinka, Cyril; Novakova, Zora; Hin, Niyada; Bím, Daniel; Ferraris, Dana V; Duvall, Bridget; Kabarriti, Gabriel; Tsukamoto, Reiji; Budesinsky, Milos; Motlova, Lucia; Rojas, Camilo; Slusher, Barbara S; Rokob, Tibor András; Rulísek, Lubomír; Tsukamoto, Takashi.
Afiliação
  • Barinka C; Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic. Electronic address: cyril.barinka@ibt.cas.cz.
  • Novakova Z; Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.
  • Hin N; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
  • Bím D; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic.
  • Ferraris DV; McDaniel College, 2 College Hill, Westminster MD 21157, United States.
  • Duvall B; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
  • Kabarriti G; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
  • Tsukamoto R; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States.
  • Budesinsky M; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic.
  • Motlova L; Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.
  • Rojas C; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD 21205, United States.
  • Slusher BS; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States.
  • Rokob TA; Institute of Organic Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, 1117 Budapest, Magyar Tudósok körútja 2, Hungary.
  • Rulísek L; Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 166 10, Czech Republic. Electronic address: lubomir.rulisek@uochb.cas.cz.
  • Tsukamoto T; Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States. Electronic address: ttskuamoto@jhmi.edu.
Bioorg Med Chem ; 27(2): 255-264, 2019 01 15.
Article em En | MEDLINE | ID: mdl-30552009
A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII's preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteases / Ureia / Carbamatos / Glutamato Carboxipeptidase II Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteases / Ureia / Carbamatos / Glutamato Carboxipeptidase II Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article